Application of Follicular Phase Long-Acting GnRH Agonist Long Protocol in IVF

doi:10.12280/gjszjk.20210039

Abstract

Abstract:

Gonadotropin-releasing hormone agonist (GnRHa) has been widely used in the pituitary downregulation of in vitro fertilization and embryo transfer (IVF-ET), in which a variety of the controlled ovarian stimulation protocols were derived. The follicular phase long-acting GnRH agonist long protocol has been gradually used in the patients with endometriosis, polycystic ovary syndrome and poor ovarian response, as well as some patients with normal ovarian reserve in recent years. This protocol has the advantages of higher embryo implantation rate and clinical pregnancy rate by improving endometrial receptivity and embryonic quality, when compared with other protocols.

Key words: Ovulation induction, Superovulation, Fertilization in vitro, Ovarian reserve, Gonadotropin-releasing hormone

LI Wen-shu, LIU Xue-mei. Application of Follicular Phase Long-Acting GnRH Agonist Long Protocol in IVF[J]. Journal of International Reproductive Health/Family Planning, 2021, 40(5): 407-410.

References 27

[1]	Mao GH, Feng Z, He Y, et al. Comparisons of the effects of long-acting and short-acting GnRH agonists on embryo quality, endometrial thickness and pregnancy rate in human in vitro fertilization[J]. Arch Med Sci, 2014, 10(1):161-166. doi: 10.5114/aoms.2014.40743. doi: 10.5114/aoms.2014.40743
[2]	胡妍, 姚军, 李曼. GnRH-a降调节在IVF或ICSI中的应用[J]. 世界最新医学信息文摘, 2019, 19(8):90-91,93. doi: 10.19613/j.cnki.1671-3141.2019.08.041. doi: 10.19613/j.cnki.1671-3141.2019.08.041
[3]	Kong H, Bu Z, Guo Y, et al. Efficacy and Safety of In Vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI) Among Patients with Endometriosis After a Shortened Protocol of Long-Term Pituitary Downregulation[J]. Med Sci Monit, 2019, 25:4377-4383. doi: 10.12659/MSM.916447. doi: 10.12659/MSM.916447 URL
[4]	Cao X, Chang HY, Xu JY, et al. The effectiveness of different down-regulating protocols on in vitro fertilization-embryo transfer in endometriosis: a meta-analysis[J]. Reprod Biol Endocrinol, 2020, 18(1):16. doi: 10.1186/s12958-020-00571-6. doi: 10.1186/s12958-020-00571-6 URL
[5]	Georgiou EX, Melo P, Baker PE, et al. Long-term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with endometriosis[J]. Cochrane Database Syst Rev, 2019, 2019(11):CD013240. doi: 10.1002/14651858.CD013240.pub2. doi: 10.1002/14651858.CD013240.pub2
[6]	徐嘉宁, 李妍, 于文竹, 等. 三种降调节促排方案对子宫内膜异位症患者IVF-ET结局的影响[J]. 生殖医学杂志, 2019, 28(2):123-128. doi: 10.3969/j.issn.1004-3845.2019.02.005. doi: 10.3969/j.issn.1004-3845.2019.02.005
[7]	张帆. 卵泡期长效长方案与黄体期短效长方案在卵巢储备良好患者IVF-ET中的应用比较[J]. 中国优生与遗传杂志, 2019, 27(2):245-246,223. doi: 10.13404/j.cnki.cjbhh.2019.02.044. doi: 10.13404/j.cnki.cjbhh.2019.02.044
[8]	Geng Y, Xun Y, Hu S, et al. GnRH antagonist versus follicular-phase single-dose GnRH agonist protocol in patients of normal ovarian responses during controlled ovarian stimulation[J]. Gynecol Endocrinol, 2019, 35(4):309-313. doi: 10.1080/09513590.2018.1528221. doi: 10.1080/09513590.2018.1528221 URL
[9]	王璐璐, 孙丽君, 冯营营, 等. 3种降调长方案对卵巢储备功能正常不孕患者IVF/ICSI促排卵效果的比较性研究[J]. 现代妇产科进展, 2019, 28(8):597-601. doi: 10.13283/j.cnki.xdfckjz.2019.08.008. doi: 10.13283/j.cnki.xdfckjz.2019.08.008
[10]	Xu B, Geerts D, Hu S, et al. The depot GnRH agonist protocol improves the live birth rate per fresh embryo transfer cycle, but not the cumulative live birth rate in normal responders: a randomized controlled trial and molecular mechanism study[J]. Hum Reprod, 2020, 35(6):1306-1318. doi: 10.1093/humrep/deaa086. doi: 10.1093/humrep/deaa086 URL
[11]	赵志明, 郝桂敏, 崔娜, 等. 早卵泡期长效长方案对多囊卵巢综合征患者体外受精临床结局的影响[J]. 中国计划生育学杂志, 2018, 26(8):709-713. doi: 10.3969/j.issn.1004-8189.2018.08.015. doi: 10.3969/j.issn.1004-8189.2018.08.015
[12]	徐嘉文, 陈建国, 林芸, 等. 多囊卵巢综合征患者应用拮抗剂方案与卵泡期长效方案对妊娠结局的影响[J]. 中国妇幼保健, 2020, 35(6):1098-1101. doi: 10.19829/j.zgfybj.issn.1001-4411.2020.06.042. doi: 10.19829/j.zgfybj.issn.1001-4411.2020.06.042
[13]	刘文霞, 王碧君, 刘曼曼, 等. 早卵泡期长效长方案与拮抗剂方案用于高龄多囊卵巢助孕效果比较[J]. 中国计划生育学杂志, 2020, 28(6):908-911. doi: 10.3969/j.issn.1004-8189.2020.06.031. doi: 10.3969/j.issn.1004-8189.2020.06.031
[14]	罗颖鎏, 陈圆辉, 王倩, 等. 拮抗剂方案与卵泡期长效长方案应用于卵巢低反应波塞冬1组患者的疗效比较[J]. 生殖医学杂志, 2020, 29(9):1137-1142. doi: 10.3969/j.issn.1004-3845.2020.09.004. doi: 10.3969/j.issn.1004-3845.2020.09.004
[15]	王含必, 汤鲜, 邓成艳, 等. 波塞冬分类标准下患者体外受精/卵胞质内单精子注射妊娠结局的影响因素[J]. 中华生殖与避孕杂志, 2019, 39(9):706-711. doi: 10.3760/cma.j.issn.2096-2916.2019.09.003. doi: 10.3760/cma.j.issn.2096-2916.2019.09.003
[16]	Li F, Ye T, Kong H, et al. Efficacies of different ovarian hyperstimulation protocols in poor ovarian responders classified by the POSEIDON criteria[J]. Aging(Albany NY), 2020, 12(10):9354-9364. doi: 10.18632/aging.103210. doi: 10.18632/aging.103210
[17]	李欢, 李东晗, 陈圆辉, 等. 拮抗剂方案与早卵泡期长效长方案应用于波塞冬2型POR患者IVF-ET结局的比较[J]. 生殖医学杂志, 2020, 29(3):300-305. doi: 10.3969/j.issn.1004-3845.2020.03.004. doi: 10.3969/j.issn.1004-3845.2020.03.004
[18]	代玮, 胡琳莉. 卵泡期长效长方案在低反应人群中的应用[J]. 生殖医学杂志, 2019, 28(10):1125-1129. doi: 10.3969/j.issn.1004-3845.2019.10.004. doi: 10.3969/j.issn.1004-3845.2019.10.004
[19]	Edwards RG. Clinical approaches to increasing uterine receptivity during human implantation[J]. Hum Reprod, 1995, 10(Suppl 2):60-66. doi: 10.1093/humrep/10.suppl_2.60. doi: 10.1093/humrep/10.suppl_2.60
[20]	许虹, 康小玲, 徐丽清, 等. 2种内膜准备方案对反复种植失败患者子宫内膜孕激素受体和整合素αⅤβ3表达的影响[J]. 国际生殖健康/计划生育杂志, 2020, 39(1):12-14,25. doi: 10.3969/j.issn.1674-1889.2020.01.002. doi: 10.3969/j.issn.1674-1889.2020.01.002
[21]	Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina)[J]. J Am Coll Cardiol, 2002, 40(7):1366-1374. doi: 10.1016/s0735-1097(02)02336-7. doi: 10.1016/s0735-1097(02)02336-7 pmid: 12383588
[22]	Song J, Sun X, Qian K. Endometrial but not Ovarian Response is Associated With Clinical Outcomes and can be Improved by Prolonged Pituitary Downregulation in Patients With Thin and Medium Endometrium[J]. Reprod Sci, 2019, 26(11):1409-1416. doi: 10.1177/1933719118816835. doi: 10.1177/1933719118816835 URL
[23]	周雪源, 闻姬, 孔伟, 等. EMs患者长效GnRHa降调节后人工周期行FET的临床结局[J]. 国际生殖健康/计划生育杂志, 2019, 38(3):194-196. doi: 10.3969/j.issn.1674-1889.2019.03.004. doi: 10.3969/j.issn.1674-1889.2019.03.004
[24]	李崑瑜, 汤小晗, 卢美松. HOXA10及相关微小RNA在子宫内膜异位症中的研究进展[J]. 国际妇产科学杂志, 2021, 48(1):10-14. doi: 10.12280/gjfckx.20200904. doi: 10.12280/gjfckx.20200904
[25]	Li F, Zhang M, Zhang Y, et al. GnRH analogues may increase endometrial Hoxa10 promoter methylation and affect endometrial receptivity[J]. Mol Med Rep, 2015, 11(1):509-514. doi: 10.3892/mmr.2014.2680. doi: 10.3892/mmr.2014.2680 URL
[26]	Polan ML, Daniele A, Russell JB, et al. Ovulation induction with human menopausal gonadotropin compared to human urinary follicle-stimulating hormone results in a significant shift in follicular fluid androgen levels without discernible differences in granulosa-luteal cell function[J]. J Clin Endocrinol Metab, 1986, 63(6):1284-1291. doi: 10.1210/jcem-63-6-1284. doi: 10.1210/jcem-63-6-1284 URL
[27]	Tesarik J, Hazout A, Mendoza C. Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation[J]. Hum Reprod, 2004, 19(5):1176-1180. doi: 10.1093/humrep/deh235. doi: 10.1093/humrep/deh235 pmid: 15070873